FarSite™ Virtual Visits: Bringing Patients and Investigators Closer Together

Post By Sarah Nolan

Virtual clinical trials can significantly reduce the need for patients to travel to sites, allowing many more patients per site to participate. This enrollment effect can lower the total number of sites required in a trial, leading to powerful cost reductions. Virtual trials also offer other advantages, such as improved data collection and patients who are more involved and committed to the trial.

New technologies are driving the trend towards virtual trials, including mobile, wearable and implantable devices, microsensors, apps, data transfer by Bluetooth, Cloud environments and advanced analytics. As these innovations capture and process data in new ways, a key element must be preserved: the personal interaction between patient and investigator. The crux of every trial will continue to be the evaluation of a patient by a skilled investigator who is able to discern both objective and subjective input on the patient’s health status.   

The challenge is to foster an intimate, positive patient visit on a remote basis. FarSite Virtual Visits rises to this challenge, providing an engaging virtual experience between patients and investigators. Visits are easy to schedule, logon and interact, with a clean interface and intuitive controls. Two-way video supports a personal experience, and the platform incorporates versatile functions with complete data capture.

Sponsors can select the features and activities on FarSite that match the patient visit plan for each clinical trial. These features include live video, screen view, documents, feedback, checklists, forms, notes, multi-party visits and a help button. Importantly, all data generated during a virtual visit is captured within this uniquely compliant, validated platform.

As study sponsors transition to trials with more virtual elements, FarSite Virtual Visits is setting the standard as a virtual platform that optimizes the all-important relationship between patient and investigator.

To learn more, watch the short video below, or click here

 

Tags: